News | January 07, 2025
Japan Health Authority approves Biocon Biologics’ Ustekinumab BS, Biosimilar to J&J's Stelara
The biosimilar Ustekinumab has been developed and manufactured by the company
The biosimilar Ustekinumab has been developed and manufactured by the company
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
The transaction is expected to result in approximately $175 million to support further development of IMG-007
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Subscribe To Our Newsletter & Stay Updated
